Where have you read that?OTO-413 seems to only target acute hidden hearing loss, not chronic?
I believe OTO-313 was initially targeting acute tinnitus. Have not seen that with OTO-413.So i have read some pages from this topic and if I am right, OTO-413 seems to only target acute hidden hearing loss, not chronic?
The exclusion criteria for OTO-413 is because some patients might not notice the improvement in hearing due to their LOUD tinnitus. Nothing more.OTO-313: early onset tinnitus
OTO-413: having tinnitus is exclusion criteria
Isn't OTO-413 designed to repair hair cells? If so, why is tinnitus excluded, considering noise-induced tinnitus is caused by bent or damaged hair cells?The exclusion criteria for OTO-413 is because some patients might not notice the improvement in hearing due to their LOUD tinnitus. Nothing more.
Answered in the post above yours. It's about getting a clean result in a clinical trial. It's not about equity.isn't OTO-413 designed to repair hair cells? If so, why is tinnitus excluded, considering noise-induced tinnitus is caused by bent or damaged hair cells?
You don't understand. If OTO-413 repaired damage to hair cells, then those with noise-induced tinnitus should be a shoo-in for the treatment because success could also be measured by a reduction in tinnitus.Answered in the post above yours. It's about getting a clean result in a clinical trial. It's not about equity.
OTO-413 doesn't work by repairing hair cells. It works by regenerating cochlear synapses.You don't understand. If OTO-413 repaired damage to hair cells, then those with noise-induced tinnitus should be a shoo-in for the treatment because success could also be measured by a reduction in tinnitus.
Unless it actually worked, I think it wouldn't be too hard to measure if people said "ooh, I don't have tinnitus anymore." I do think with a lot of these drugs it's a shame there's not a scatter gun approach at the start. Get a large group of people with different issues then narrow stuff down. With the ears it's all guesswork and theory at the moment. What if restoring the synapse does nothing on its own for hearing, but it could work for tinnitus or ear pain / sensitivity? They could be onto a winner but we will never know.They're taking a hearing loss treatment to the FDA, not a tinnitus treatment. Any improvement in tinnitus would be a flow-on result of improvement in hearing. Improved hearing is the primary outcome.
In any case, tinnitus is notoriously difficult to measure. If including tinnitus sufferers muddies the waters when it comes to measuring hearing, where's the upside in including them? It makes getting FDA approval a little less likely.
They are one in the same man.They're taking a hearing loss treatment to the FDA, not a tinnitus treatment. Any improvement in tinnitus would be a flow-on result of improvement in hearing. Improved hearing is the primary outcome.
In any case, tinnitus is notoriously difficult to measure. If including tinnitus sufferers muddies the waters when it comes to measuring hearing, where's the upside in including them? It makes getting FDA approval a little less likely.
Then why are they excluding people with tinnitus? Aren't some forms of tinnitus caused by dead or broken synapses?OTO-413 doesn't work by repairing hair cells. It works by regenerating cochlear synapses.
I think tinnitus is just another layer of complexity for a study looking at hearing restoration.Then why are they excluding people with tinnitus? Aren't some forms of tinnitus caused by dead or broken synapses?
Furthermore, why did Otonomy state that OTO-413 repairs the ear rather than regenerates?
But can't they list tinnitus as a secondary outcome?I think tinnitus is just another layer of complexity for a study looking at hearing restoration.
Nope, only hearing.But can't they list tinnitus as a secondary outcome?
I don't think this is the drug we're waiting for. They said on the Tinnitus Talk Podcast that there were no reports of tinnitus improving with the usage of the drug in the trials. Maybe the drug would have an application as an adjunct therapy with Dr. Susan Shore's device or something; but outside of that I remain skeptical.Nope, only hearing.
How is that different from regenerating hair cells?OTO-413 doesn't work by repairing hair cells. It works by regenerating cochlear synapses.
They also are excluding patients with bothersome tinnitus from the trial. So, chances are, if someone did have tinnitus that wasn't "bothersome," any improvement wouldn't be significant on a TFI anyway.I don't think this is the drug we're waiting for. They said on the Tinnitus Talk Podcast that there were no reports of tinnitus improving with the usage of the drug in the trials. Maybe the drug would have an application as an adjunct therapy with Dr. Susan Shore's device or something; but outside of that I remain skeptical.
Upon further investigation, many experts in the field are theorizing that cochlear synaptopathy may in fact be responsible for some tinnitus and hyperacusis. Check out this quote from Dr. Charles Liberman. There may be a benefit of such drugs for those suffering from tinnitus or hyperacusis.They also are excluding patients with bothersome tinnitus from the trial. So, chances are, if someone did have tinnitus that wasn't "bothersome," any improvement wouldn't be significant on a TFI anyway.
The difference is synapses are more vulnerable and take the brunt of the damage.They also are excluding patients with bothersome tinnitus from the trial. So, chances are, if someone did have tinnitus that wasn't "bothersome," any improvement wouldn't be significant on a TFI anyway.
Now I'm confused. Do we assume OTO-413 may be the treatment we're looking for or not?The difference is synapses are more vulnerable and take the brunt of the damage.
@OptimusPrimed is spot on, that is the primary underlying cause for tinnitus and hyperacusis. I fully believe that regenerating the cochlear synapses will be the most effective way possible to reverse tinnitus. All the lost sensory input that is causing the overstimulation of neurons and ringing sounds would be restored.
Could be but we have yet to get any evidence at all that regenerative medicine impacts tinnitus. I'm waiting for the first hint of evidence that it will help, right now it is all just theory. That being said it makes sense to me.Do we assume OTO-413 may be the treatment we're looking for or not?
When I first joined up here I thought tinnitus was all about damaged or missing hair cells.Could be but we have yet to get any evidence at all that regenerative medicine impacts tinnitus. I'm waiting for the first hint of evidence that it will help, right now it is all just theory. That being said it makes sense to me.
Upon further investigation, many experts in the field are theorizing that cochlear synaptopathy may in fact be responsible for some tinnitus and hyperacusis. Check out this quote from Dr. Charles Liberman. There may be a benefit of such drugs for those suffering from tinnitus or hyperacusis.
In Conversation with Professor Charles Liberman
Since acoustic overexposure is the most reliable way to produce tinnitus and hyperacusis in humans, and since both perceptual anomalies can occur without audiometric shifts, and since auditory-nerve synapses are the most vulnerable elements in noise damage, it was natural to hypothesise that synaptopathy might be a key elicitor of tinnitus and hyperacusis. There is now evidence from animal models that this type of peripheral neural loss is transformed into hyperactivity (both spontaneous and sound-evoked) throughout the central auditory pathways, as central neuronal circuits rebalance the excitatory and inhibitory inputs in response to decreasing ascending signals. It's intriguing that, in some cochlear implant users, simply turning on the implant, and thereby restoring spontaneous activity to heretofore silent auditory nerve fibres, can attenuate the tinnitus percept. It suggests that reconnecting silenced spiral ganglion neurons to hair cells could also be a treatment for tinnitus. It might also be a cure for some types of hyperacusis, but see below.
These are great points, and I am aware of and agree that synaptopathy may be one of the underlying conditions causing tinnitus and/or hyperacusis. As someone who had progressive synaptopathy issues for about a decade prior to getting "hear it all time" tinnitus, I can anecdotally say there may be a correlation.The difference is synapses are more vulnerable and take the brunt of the damage.
@OptimusPrimed is spot on, that is the primary underlying cause for tinnitus and hyperacusis. I fully believe that regenerating the cochlear synapses will be the most effective way possible to reverse tinnitus. All the lost sensory input that is causing the overstimulation of neurons and ringing sounds would be restored.
It's great to have someone who knows the jargon and puts an optimistic slant on it. Not much I can add with my limited knowledge of medicine or the auditory system other than to say that Otonomy is fighting its corner in Bureaucracy-land where the costs in time and money are very high and where hearing tests in a sample (PTA WIN etc) yield concrete results whereas tinnitus tests get kind of mixed up with mood and placebo and might vary over time.These are great points, and I am aware of and agree that synaptopathy may be one of the underlying conditions causing tinnitus and/or hyperacusis. As someone who had progressive synaptopathy issues for about a decade prior to getting "hear it all time" tinnitus, I can anecdotally say there may be a correlation.
However, that doesn't change that Otonomy isn't accepting patients with "bothersome tinnitus" into the OTO-413 trial, nor are they testing for it. So, within the scope of the Phase 2 in-progress, unfortunately they won't comment on tinnitus improvement or be able to provide any data/evidence that OTO-413 improves the tinnitus symptom vs placebo.
They will either add tinnitus to a Phase 3 / Pivotal as an experimental outcome, or we'll have to wait and see what the early tinnitus-having recipients of the drug say.
I appreciate the comment, however I am but a simple liquid hydrocarbon.It's great to have someone who knows the jargon and puts an optimistic slant on it. Not much I can add with my limited knowledge of medicine or the auditory system other than to say that Otonomy is fighting its corner in Bureaucracy-land where the costs in time and money are very high and where hearing tests in a sample (PTA WIN etc) yield concrete results whereas tinnitus tests get kind of mixed up with mood and placebo and might vary over time.
So the way to get FDA approval is with concrete results.
Once the drug hits the market, well, we can try for ourselves once the good doctor prescribes it.
I appreciate the comment, however I am but a simple liquid hydrocarbon.
The requirements to get a drug to product are simple: Identify a clear patient population, demonstrate that a drug is safe or with non-severe side effects on that population, demonstrate that it reliably performs better than placebo.
The more variables the trial adds, reduces the clarity on patient population. That puts the likelihood of this product (and the underlying work / knowledge) of ever reaching the final production state.
Forgive me for nit-picking your informative post -- which seems to have gained some resonance among readers here by the way -- but I'm apprehensive about the order in which these are carried out.Great points that everyone needs to understand. They're testing a drug to restore hearing. They don't want to have anyone with any conditions that could affect their maximum perception of improvement. It's why they exclude Meneire's and others. They want to show as large gains in hearing threshold in the trial as they can for information and marketing purposes and unfortunately for a lot that want to participate in the trial, that will be easier in people with only hearing loss and no other conditions.
It should still help tinnitus if hearing is regenerated as a result of it. There are 2 parts to this - regenerating the physical parts of the cochlea, and having the brain rewire itself to reconnect the signal processing back to those frequencies to bring the feedback loop to homeostasis and thus quiet the noise. I think most of us would be happy with any improvements we can get.